- Home
- RPRX vs OKTA Comparison
RPRX vs OKTA Comparison
Compare RPRX & OKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | OKTA |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 23.8B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RPRX | OKTA |
|---|---|---|
| Price | $63.63 | $168.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 36 |
| Target Price | $51.40 | ★ $103.60 |
| AVG Volume (30 Days) | 2.6M | ★ 3.5M |
| Earning Date | 05-06-2026 | 05-26-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 2083.33 |
| EPS | 0.71 | ★ 1.07 |
| Revenue | $2,378,193,000.00 | ★ $2,919,000,000.00 |
| Revenue This Year | $38.63 | $11.27 |
| Revenue Next Year | $4.73 | $9.36 |
| P/E Ratio | ★ $88.89 | $152.49 |
| Revenue Growth | 5.06 | ★ 11.84 |
| 52 Week Low | $34.63 | $62.66 |
| 52 Week High | $63.29 | $174.85 |
Technical Indicators
Market Signals| Indicator | RPRX | OKTA |
|---|---|---|
| Relative Strength Index (RSI) | 68.15 | 61.84 |
| Support Level | $38.07 | $130.33 |
| Resistance Level | N/A | $174.85 |
| Average True Range (ATR) | 1.26 | 8.14 |
| MACD | 0.19 | 2.50 |
| Stochastic Oscillator | 97.35 | 87.41 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About OKTA Okta Inc.
Okta is a cloud-native security company specializing in identity and access management. The San Francisco-based firm went public in 2017 and serves two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees, contractors, and partners to securely access its cloud-based and on-premises resources. The firm's customer offering, delivered via its Auth0 platform, allow clients to provide secure access experiences to their own end users.